Melanotan II

Melanotan II is a synthetic alpha-MSH analog that induces skin tanning without UV exposure by activating MC1R. It also affects sexual arousal and appetite through non-selective melanocortin receptor binding, and is one of the most widely used cosmetic peptides despite lacking regulatory approval.

Melanotan II is a synthetic cyclic analog of alpha-melanocyte stimulating hormone (α-MSH), with the structure Ac-Nle4-Asp5-His6-D-Phe7-Arg8-Trp9-Lys10-α-MSH(4-10)-NH2. The lactam bridge between the aspartate and lysine residues locks the peptide into a constrained ring, which both raises potency at melanocortin receptors far above native α-MSH and greatly extends its resistance to enzymatic breakdown. It was designed in the 1980s and 1990s at the University of Arizona by Mac Hadley, Victor Hruby, Robert Dorr, and Norman Levine, and the original therapeutic rationale was genuinely a public-health one: if fair-skinned people could be induced to produce protective eumelanin without ultraviolet exposure, the reasoning went, sun-driven skin cancer incidence might fall.

That rationale never made it through clinical development. Melanotan II reached only small pilot studies — the published human tanning work involves single-digit numbers of subjects — and the program was not carried into the large controlled trials that would have been needed for approval. What survived from the University of Arizona work were two derivative drugs, both of which are approved and neither of which is Melanotan II. Bremelanotide (marketed as Vyleesi), a related melanocortin agonist developed from the same research line, was approved by the FDA on June 21, 2019 for acquired, generalized hypoactive sexual desire disorder in premenopausal women. Afamelanotide (marketed as SCENESSE), the linear α-MSH analog historically called Melanotan-I and a predominantly MC1R-selective agonist, was approved on October 8, 2019 as a 16 mg subcutaneous implant given every two months to increase pain-free light exposure in adults with erythropoietic protoporphyria. Afamelanotide is the only approved α-MSH analog used for pigmentary purposes, and it is a distinct molecule from Melanotan II.

Melanotan II's actual present-day existence is as a grey-market cosmetic injectable. It is sold online as lyophilized powder and, less commonly, as nasal spray, reconstituted and injected by users without medical supervision. The user base is substantial and has been studied as a public health phenomenon in its own right: Evans-Brown and colleagues raised it in the BMJ in 2009, Callaghan surveyed the underground market in the Dermatology Online Journal in 2018, and Gilhooley and colleagues analyzed user discussion forums in Dermatology in 2021. Product identity and purity are not verified in this supply chain, which means adverse events reported by users cannot always be attributed to Melanotan II itself rather than to contaminants, incorrect substances, or dosing errors.

The safety picture is the part of this entry that matters most. Melanotan II activates melanocytes, and the published case-report literature documents new and darkening moles, eruptive and dysplastic nevi, and a small number of melanomas arising from pre-existing moles during or shortly after use. A 2017 International Journal of Dermatology review by Habbema and colleagues, which remains the standard reference on the topic, identified four such melanoma case reports and concluded that while conclusive causal evidence is lacking, the association warrants clinical awareness. Separate case reports describe rhabdomyolysis with systemic toxicity, priapism, and renal infarction. The FDA, the Australian TGA, the UK MHRA, and multiple other national health agencies have issued warnings against cosmetic use. Anyone using it should understand that increased melanocytic activity can also complicate visual skin cancer screening.

Melanotan II is a non-selective agonist across the melanocortin receptorreceptor family, binding MC1R, MC3R, MC4R, and MC5R. This promiscuity is the direct explanation for both its intended effect and essentially all of its side effects, because the five melanocortin receptors sit in unrelated physiological systems and cannot be engaged independently by a non-selective ligand. Native α-MSH is similarly non-selective but is degraded within minutes; the cyclic lactam constraint in Melanotan II confers both higher potency and metabolic stability, so a single dose engages all four receptor types for hours.

The tanning effect runs through MC1R on epidermal melanocytes. MC1R is a Gs-coupled receptor; agonism raises intracellular cAMP, activates protein kinase A, and drives CREB-mediated transcription of MITF, the master melanocyte transcription factor. MITF in turn upregulates tyrosinase and the tyrosinase-related proteins, shifting melanin synthesis toward eumelanin — the darker, more photoprotective pigment — rather than pheomelanin. This is the same pathway UV exposure recruits, but activated pharmacologically and therefore without the DNA damage that normally initiates it. MC1R is a highly polymorphic gene in humans, and loss-of-function variants common in red-haired and very fair-skinned people impair signaling, which is part of why response is variable between individuals.

The sexual effects run through central MC3R and MC4R in the hypothalamus and spinal cord rather than through any peripheral vascular mechanism. This distinguishes Melanotan II from PDE5 inhibitors such as sildenafil, which act on penile smooth muscle: melanocortin agonism appears to act on the pro-erectile pathway upstream, in the brain, which is why the human studies reported increases in subjective sexual desire alongside erectile response. Dorr's 1996 Phase I report described a characteristic 'stretching and yawning complex' preceding spontaneous erections that lasted one to five hours after dosing — a behavioral signature long known from melanocortin pharmacology in animals. It was this observation, made incidentally during a tanning study, that redirected part of the program toward sexual dysfunction and ultimately produced bremelanotide.

Appetite suppression is mediated principally by MC4R in the hypothalamic paraventricular nucleus, the same receptor whose loss-of-function mutations are the most common monogenic cause of human obesity. MC5R, engaged as well, is involved in exocrine and sebaceous gland function. The nausea that dominates the reported side effect profile is thought to arise from central melanocortin activation rather than any direct gastrointestinal action, which is consistent with its appearance at low doses and its tendency to attenuate with repeated exposure. Facial flushing reflects melanocortin effects on vascular tone.

The human evidence for Melanotan II consists of a small number of pilot studies conducted at the University of Arizona in the 1990s, plus a substantially larger body of adverse-event case reports accumulated since it entered grey-market use. There is no Phase III data, and no trial of any size has evaluated the long-term safety of the doses and durations used cosmetically.

The foundational tanning study is Dorr and colleagues in Life Sciences, 1996 — a single-blind, alternating-day, placebo-controlled pilot in three normal male volunteers. Subjects received subcutaneous Melanotan II or saline daily Monday through Friday for two consecutive weeks, starting at 0.01 mg/kg and escalating in 0.005 mg/kg increments to 0.03 mg/kg in two subjects and 0.025 mg/kg in one. Two of the three showed increased pigmentation of the face, upper body, and buttock by quantitative reflectance and visual assessment one week after dosing ended. The 0.03 mg/kg dose produced Grade II somnolence and fatigue in one of the two subjects who received it, and mild nausea was reported at most dose levels. The authors recommended 0.025 mg/kg/day for future Phase I work. This is the study most often cited as establishing that Melanotan II tans humans, and it is important to be clear about its size: three people.

The sexual-function evidence is somewhat stronger in design though still small. Wessells and colleagues published a double-blind, placebo-controlled crossover study in men with psychogenic erectile dysfunction in the Journal of Urology in 1998, then extended the work to men with organic risk factors in Urology in 2000. In the 2000 study, ten men received 0.025 mg/kg Melanotan II and placebo by subcutaneous injection twice each, with erections monitored over six hours by RigiScan and visual analog scales. Subjectively reported erections followed 12 of 19 Melanotan II injections versus 1 of 21 placebo injections; mean duration of substantial tip rigidity at or above 80 percent was 45.3 minutes versus 1.9 minutes for placebo (P = 0.047); mean rigidity scored 6.9 on a 0-10 scale; and sexual desire increased significantly relative to placebo. Severe nausea occurred with 4 of 19 injections — a tolerability signal that is one reason the more receptor-selective bremelanotide, rather than Melanotan II, was carried forward.

The appetite and metabolic literature is animal-only. Rodent studies have shown substantial reductions in food intake through MC4R agonism, and Melanotan II is a standard laboratory tool for probing melanocortin control of feeding, but no controlled human trial has evaluated it for weight loss and it should not be regarded as a weight-loss agent.

The post-marketing case-report literature is where most of what is known about real-world Melanotan II use resides. Cardones and Grichnik described α-MSH-induced eruptive nevi in the Archives of Dermatology in 2009. Paurobally and colleagues reported melanotan-associated melanoma in the British Journal of Dermatology in 2011, and several further reports of eruptive dysplastic nevi followed from groups in Ireland, Spain, Sweden, and Australia. Nelson and colleagues reported systemic toxicity with rhabdomyolysis in Clinical Toxicology in 2012; Dreyer and colleagues reported priapism in BMJ Case Reports in 2019; Peters and colleagues reported renal infarction in CEN Case Reports in 2020. Habbema and colleagues' 2017 International Journal of Dermatology review synthesized this literature, noting four melanoma case reports arising from existing moles during or shortly after melanotan use, and stressed that the unverified preparation, administration, and dosing of illicit product is itself an independent risk beyond the pharmacology.

A fair summary is that Melanotan II demonstrably tans humans and demonstrably affects sexual response, both on very small samples; that its side effect burden at effective doses was significant enough to steer its own developers toward more selective successor compounds; and that the melanocytic changes documented in case reports are a plausible-mechanism concern in a compound whose entire purpose is to stimulate melanocytes.[1][2][3][4][5][6][7][8][9][10][11][12][13][14][15]

Peptides commonly paired with Melanotan II for synergistic effects.